These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24102472)

  • 1. Pathophysiology and pharmacologic treatment of venous thromboembolism.
    Bain J; Oyler DR; Smyth SS; Macaulay TE
    Curr Drug Targets; 2014 Feb; 15(2):199-209. PubMed ID: 24102472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
    Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
    J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the management of venous thromboembolism.
    Schulman S
    Best Pract Res Clin Haematol; 2012 Sep; 25(3):361-77. PubMed ID: 22959552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism.
    Riva N; Ageno W
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1035-51. PubMed ID: 27637306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
    Fanola CL
    Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New anticoagulants for the treatment of venous thromboembolism.
    Prandoni P; Dalla Valle F; Piovella C; Tormene D; Pesavento R
    Minerva Med; 2013 Apr; 104(2):131-39. PubMed ID: 23514989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New anticoagulants in the prevention and treatment of venous thromboembolism].
    Keltai M; Keltai K
    Orv Hetil; 2011 Jun; 152(25):983-92. PubMed ID: 21642050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
    Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
    J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children.
    Male C; Monagle P; Albisetti M; Brandão LR; Young G
    J Pediatr; 2022 Jan; 240():14-23. PubMed ID: 34687696
    [No Abstract]   [Full Text] [Related]  

  • 11. The evolution of anticoagulant therapy.
    Franchini M; Liumbruno GM; Bonfanti C; Lippi G
    Blood Transfus; 2016 Mar; 14(2):175-84. PubMed ID: 26710352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous Thromboembolism in Children: From Diagnosis to Management.
    Lassandro G; Palmieri VV; Palladino V; Amoruso A; Faienza MF; Giordano P
    Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32664502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and emerging options in the management of venous thromboembolism.
    Jaffer AK; Brotman DJ; Michota F
    Cleve Clin J Med; 2005 Apr; 72 Suppl 1():S14-23. PubMed ID: 15853175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis.
    Vedovati MC; Germini F; Agnelli G; Becattini C
    Chest; 2015 Feb; 147(2):475-483. PubMed ID: 25211264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism management: where do novel anticoagulants fit?
    Spyropoulos AC; Turpie AG
    Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts for the prevention of venous thromboembolism.
    Bramlage P; Pittrow D; Kirch W
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():4-11. PubMed ID: 15701142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.
    Chan NC; Bhagirath V; Eikelboom JW
    Vasc Health Risk Manag; 2015; 11():343-51. PubMed ID: 26170684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.